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Background. Before the introduction of combination antiretroviral therapy (cART), patients infected with the
human immunodeﬁciency virus (HIV) rarely died of liver disease. In resource-rich countries, cART dramatically
increased longevity. As patients survived longer, hepatitis C virus (HCV) infection became a leading cause of
death; however, because patients with AIDS continue to have 5-fold greater mortality than non-AIDS patients, it
is unclear whether HCV infection increases mortality in them.
Methods. In this investigation, which is part of the Longitudinal Studies of the Ocular Complications of
AIDS, plasma banked at enrollment from 2025 patients with AIDS as deﬁned by the Centers for Disease Control
and Prevention were tested for HCV RNA and antibodies.
Results. Three hundred thirty-seven patients had HCV RNA (chronic infection), 91 had HCV antibodies and
no HCV RNA (cleared infection), and 1597 had no HCV markers. Median CD4
+ T-cell counts/µL were 200
(chronic), 193 (cleared), and 175 (no markers). There were 558 deaths. At a median follow-up of 6.1 years,
patients with chronic HCV had a 50% increased risk of mortality compared with patients with no HCV markers
(relative risk [RR], 1.5; 95% conﬁdence interval [CI], 1.2–1.9; P= .001) in an adjusted model that included known
risk factors. Mortality was not increased in patients with cleared infection (RR, 0.9; 95% CI, .6–1.5; P=.82). In
patients with chronic HCV, 20.4% of deaths were liver related compared with 3.8% in patients without HCV.
Conclusions. Chronic HCV infection is independently associated with a 50% increase in mortality among
patients with a diagnosis of AIDS, despite competing risks. Effective HCV treatment may beneﬁt HIV/HCV-
coinfected patients with AIDS.
In the early years of the human immunodeﬁciency
virus (HIV)/AIDS epidemic, few patients died of liver
disease because they succumbed to other illnesses
before progressing to end-stage liver disease. In the 17
years since the advent of combination antiretroviral
therapy (cART), survival of HIV-positive individuals
has increased, especially in resource-rich countries,
and liver disease has emerged as a major cause of
death [1–5]. The majority of liver-related deaths in
HIV-positive patients occur in people with chronic
hepatitis C virus (HCV) infection [6, 7]. HCV infects
about 30% of the HIV-positive individuals in the
United States and Europe [8]. A recent meta-analysis
showed that the overall mortality risk ratio for HIV/
HCV coinfected patients compared with HIV monoin-
fected patients is increased by about 35% [9]. It is un-
clear whether these results apply to patients with AIDS
as deﬁned by the Centers for Disease Control and Pre-
vention (CDC) in the cART era, however, because their
mortality rate continues to be approximately 5 times
higher than that of HIV-positive patients without a
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the mortality risk of HCV infection in current patients with
AIDS, just as they did in the early years of the epidemic. Out-
comes in patients with a diagnosis of AIDS remain an impor-
tant public health concern. In 2009, almost 35000 people were
diagnosed with AIDS in the United States [11].
To determine the impact of HCV infection on survival, this
study compared mortality in a large cohort of AIDS patients.
The 2025 study subjects were enrolled in the Longitudinal
Studies of the Ocular Complications of AIDS (LSOCA) and
were followed prospectively for a median of >6 years. LSOCA is
one of only a few cohort studies limited to persons diagnosed
with AIDS but without further exclusion criteria. It focuses ex-
clusively on the era following the introduction of cART [12].
METHODS
Study Subjects and Design
Subjects were aged ≥13 years with a diagnosis of AIDS accord-
ing to the 1993 CDC deﬁnition [13]. The LSOCA population is
similar in age, race, and sex to the US AIDS population, except
it has a lower percentage of patients with a history of injection
drug use [14]. At enrollment, data on demographics and past
medical history were collected, and physical and ophthalmo-
logic examinations were performed. Cytomegalovirus retinitis
(CMV-R) was diagnosed by a LSOCA-certiﬁed ophthalmologist
[12, 15]. Follow-up occurred every 3 months for patients with
an ocular opportunistic infection (eg, CMV-R) and every 6
months otherwise. Plasma samples were collected at baseline
and every 6 months thereafter. At a baseline-structured inter-
view subjects were asked, “Have you ever been diagnosed with
hepatitis?” Subjects responding “yes” were then asked to identify
the type(s), for example, hepatitis A virus (HAV), hepatitis B
virus (HBV), HCV, or other. One of the original objectives
of LSOCA was to collect information about factors associated
with mortality. Information on mortality was collected on an
ongoing basis. Immediate and contributing causes of death were
recorded in death reports. Combination ART was deﬁned as ≥3
antiretroviral drugs given at therapeutic levels. Most HIV type 1
RNA assays were performed using the Roche Amplicor system.
For analysis, viral loads below the lower limit of detection were
assigned a value of one-half the lower limit, and values above
the assay’s upper limit were assigned the upper limit. This study
was approved by the institutional review board at each center,
and all patients gave written informed consent.
Methods to Determine HCV Serostatus
Plasma samples collected at enrollment were analyzed. All
samples were tested for anti-HCV antibodies using the third-
generation enzyme immunoassay (EIA) version 2.0 (Abbott).
HCV RNA testing was performed on all samples with anti-HCV
antibodies and/or an EIA signal-to-noise ratio ≥0.7 and on all
samples from injection drug users (IDUs), regardless of the
HCV antibody test results, using the Roche Cobas Amplicor
Hepatitis C Virus Test, version 2.0 (lower limit of detection, 50
IU/mL). Eighteen subjects with HCV antibody–positive plasma
were missing HCV RNA results, 5 were classiﬁed as having
cleared a past HCV infection because the HCV antibody signal-
to-noise ratio was <3.8. HCV serological testing was performed
in 2008–2009. Results were sent to participating clinics with the
advice that local guidelines be followed for communicating the
results to patients. Patients with HCV RNA were considered to
have chronic infection, and patients with anti-HCV antibodies
and no HCV RNA were considered to have cleared a previous
infection. It is possible that some people in the latter group had
a false-positive antibody test and never had an HCV infection.
Data Analysis
Data available as of 31 December 2009 were included. The χ
2
test was used for categorical variables, and the Kruskal-Wallis
test was used for continuous variables. Cox regression analysis
was used for factors associated with mortality. Unless other-
wise noted, values of samples collected at enrollment were in-
cluded in the analysis. The variables included HCV serostatus,
self-reported diagnosis of HAV and/or HBV, sex, race, age,
birth cohort, education, IDU status, time since AIDS diagnosis,
diagnosis of CMV-R, cART, AIDS-deﬁning condition, CD4
+
T-cell count (at enrollment and nadir), CD8
+ T-cell count,
HIV RNA (at enrollment and maximum), platelet count, and
year of enrollment. Three adjusted models were developed: (1)
forward selection was used and only variables with P values
≤ .05 in the adjusted model were retained; (2) backward selec-
tion was used; (3) all the variables were entered into a fully
adjusted model. Maximum HIV RNA was excluded from mul-
tivariable analyses because 6% of subjects had missing data.
Follow-up time was calculated as the time from study entry to
death, to 31 December 2009, or to the date of the last study
contact for patients who were lost to follow-up. Univariate and
forward selection multiple logistic regressions were used to
identify factors associated with lack of awareness of chronic in-
fection and HCV clearance. Analyses were performed with
SAS (version 9.2) [16,17]and Stata software (version 12.1) [17].
RESULTS
Baseline Characteristics
Among the 2025 subjects, 428 (21%) had evidence of past or
current HCV infection. Of these, 337 (79%) were HCV RNA
positive, indicating chronic infection, and 91 (21%) had HCV anti-
bodies but no HCV RNA, indicating past infection. Subjects with
HCV infection (combined group of cleared plus chronic) were
more likely to be female, black, older at the time of enrollment,
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history of injection drug use, and to have higher CD4
+ T-cell
counts (enrollment and nadir) and lower platelets. They were
less likely to have a college education, a diagnosis of CMV-R, to
use cART, and to enroll during 1998–2000 (Table 1). A CD4
+
T-cell count <200 cells/µL was the AIDS-deﬁning condition in
Table 1. Characteristics of the Population at Enrollment by Hepatitis C Virus Serostatus
HCV Serostatus
a




















Female (%) 17 30 26 19 <.0001 .53
Black race (%) 30 40 55 35 <.0001 .01
Age, y (median±SD
e) 42 43 45 43±9 <.0001 .03
Birth cohort (%) <.0001 .60
<1945 6 7 5 6
1945–1964 68 76 80 71
≥1965 25 18 15 23
College graduate (%) 36 16 12 31 <.0001 .28
HIV/AIDS history
Intravenous drug user (%) 4 33 47 13 <.0001 .02
Time since AIDS diagnosis, y (median±SD) 4.4 4.9 4.3 4.4±4.1 .79 .48
Diagnosis with CMV retinitis (%) 22 12 12 20 <.0001 .92
Currently on cART (%) 84 84 80 84 .05 .40
CD4
+ T-cell count <200 µL as AIDS-defining illness (%) 62 63 66 63 .17 .64
Self-reported hepatitis history
HCV exposed (%) 3 35 71 16 <.0001 <.0001
HBV exposed (%) 16 21 19 16 .08 .64
HAV exposed (%) 8 9 9 8 .37 .97
Exposed, type unknown (%) 8 8 5 7 .12 .33
Immunology/virology
CD4
+ T cells/μL (median±SD) 175 193 200 182±207 .03 .80
Nadir CD4
+ T cells/μL (median±SD) 30 24 57 32±62 <.0001 .003
Change from nadir CD4
+ T cells/µL (median±SD) 114 128 130 117±177 .91 .60
CD8
+ T cells/μL (median±SD) 736 800 734 739±473 .47 .38
HIV RNA, log copies/mL (median±SD) 2.8 2.8 2.6 2.8±2.0 .25 .50
Max HIV RNA, log copies/mL (median±SD) 5.3 5.4 5.3 5.3±0.8 .57 .27
Hematology
Platelets, 100000 cells/μL (median±SD) 2.14 2.18 1.96 2.12±0.68 <.0001 .01
Year of enrollment (%) .02 .86
1998–2000 43 37 35 41
2001–2005 38 42 45 40
2006–2009 19 21 20 19
There were no statistically significant (P <.01) interactions of characteristics of the population with HCV status by injection drug use status.
Abbreviations: cART, combination antiretroviral therapy; CMV, cytomegalovirus retinitis; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus;
HIV, human immunodeficiency virus; SD, standard deviation.
a Eighteen observations with positive HCV antibody and missing HCV RNA results were imputed to cleared HCV if HCV antibody signal-to-noise cutoff <3.8
(n= 5), otherwise imputed to chronic (n= 13).
b P value based on χ
2 test for categorical variables or Kruskal-Wallis test for continuous variables.
c Cleared defined as positive HCV antibody and undetectable HCV RNA.
d Chronic defined as detectable HCV RNA.
e SD estimated using pseudo-Σ.
HIV/AIDS ￿ CID 2012:55 (1 July) ￿ 139the majority of patients, regardless of HCV serostatus. The rise
in CD4
+ T cells from the nadir did not differ between patients
with and without markers of HCV exposure (P=.91; Table 1).
Compared to the group with chronic HCV, the group with past
infection had a lower percentage of blacks and IDUs and
patients were younger and had higher platelets (Table 1). In an
adjusted multiple logistic regression model, failure to clear HCV
was associated with black race, injection drug use, higher nadir
CD4
+ T-cell counts, and lower platelets (Supplemental Table 1).
Factors Associated With Mortality
There were 558 deaths at a median follow-up of 6.1 years (in-
terquartile range, 3.0–8.7). Kaplan-Meier estimates of mor-
tality for patients with chronic hepatitis C, past hepatitis C,
and no markers of HCV infection are presented in Figure 1.
Cox regression analysis was used to identify factors associated
with mortality (Table 2). Three adjusted models were ana-
lyzed. All gave similar results concerning the increased mor-
tality risk of HCV infection.
Table 2 presents the model developed using forward selec-
tion. Patients with chronic HCV infection had a 50% in-
creased mortality risk (relative risk [RR], 1.5; 95% conﬁdence
interval [CI], 1.2–1.9; P=.001) compared to patients with no
markers of HCV infection, whereas patients with prior HCV
infection did not have increased risk (RR, 0.9; 95% CI, .6–1.5;
P=.82). In addition to chronic HCV infection, increased risk
was associated with a prior diagnosis of HAV, older age at
enrollment, a diagnosis of CMV-R, higher HIV RNA, and
enrollment during 1998–2000 vs 2006–2009. Decreased risk
was associated with higher CD4
+ T-cell counts and platelets.
Neither the time since a diagnosis of AIDS (Table 2) nor the
number of interruptions of cART during follow-up (data not
shown) was related to mortality in the adjusted model.
In a backward selection model and in a fully adjusted
model that included all the variables in the univariate analysis,
the RR of chronic HCV infection was 1.5, identical to the RR
estimated in the forward selection model. In the backward se-
lection model, the 95% CI was 1.2–1.9 (P=.0007), and in the
fully adjusted model, the 95% CI was 1.2–2.0 (P=.003). In all
3 models, in addition to chronic HCV infection, increased
mortality was associated with HAV, CMV-R, higher HIV
RNA, and the year of enrollment; decreased mortality was
associated with higher CD4
+ T-cell counts (Table 2 and data
not shown). All 3 models showed that mortality risk was
approximately 50% higher in patients with chronic hepatitis C
than in patients with prior hepatitis C, but the increase was
not statistically signiﬁcant: 95% CIs were 1.0–1.5 in all 3 ad-
justed models and P values were .07.
Of the 113 deaths in patients with chronic HCV, 20.4% were
liver related, compared to only 3.8% of the 420 deaths in
patients with no markers of HCV exposure. Patients with
chronic infection were >5 times more likely to die of liver-
related causes than patients with no markers of HCV (P
<.0001). Liver-related deaths contributed to 12.0% of the 25
deaths in patients with cleared HCV. Alcohol use and HBV in-
fection may have contributed to these liver-related deaths. The
proportion of deaths related to cardiovascular disease, AIDS,
and non-AIDS-related cancer were similar between patients
with and without HCV infection (Supplementary Table 2).
Lack of Awareness of HCV Status
Because HCV infection decreases longevity and is both trans-
missible and potentially curable, we investigated patient aware-
ness of HCV. Almost one-third (100 of 337) of the subjects
with chronic hepatitis C reported that they had never received
a diagnosis of HCV infection. In a logistic regression model,
this lack of awareness was positively associated with enroll-
ment during 1998–2000 vs 2006–2009; it was not associated
with self-reported HBV infection, and it was negatively associ-
ated with self-reported HAV infection (Table 3).
Effectiveness of the Approach Used to Identify Cases of Chronic
HCV
HCV RNA testing was carried out on all samples with HCV
antibodies and all samples from subjects with a history of in-
jection drug use, 25% of the total. This approach identiﬁed
337 HCV RNA–positive samples. We performed HCV RNA
testing on 60 representative samples from low-risk patients
(non-IDUs who self-reported HCV negative status) and used
the results to estimate the percentage of HCV RNA–positive
samples (and cases of chronic infection) that we likely missed
by not testing all antibody-negative samples for HCV RNA.
HCV RNA was present in 3 of 60 samples (5%); 2 of the 3
had HCV antibodies. At a 5% positivity rate, the low-risk
Figure 1. Kaplan-Meier survival curves indicate that chronic hepatitis
C virus infection was associated with an increased mortality risk.
Abbreviation: HCV, hepatitis C virus.
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samples were anti–HCV antibody positive. This suggests that
about 25 cases were missed, and that the actual number of
HCV RNA–positive samples in the entire study group was
about 362. Of these, we identiﬁed 337, which is 93% (337 of
362) of the estimated chronic cases.
DISCUSSION
This study of patients with a diagnosis of AIDS established
that chronic HCV infection increased mortality risk by about
50% after adjustment for demographic factors, HIV status,
CMV-R, and injection drug use. It also revealed that almost
30% of the subjects with chronic HCV infection reported that
they had never been given a diagnosis of this disease. In
addition, and in keeping with previous investigations, this
study showed that black patients and patients with a history of
injection drug use were less likely to clear HCV than other
patients [18, 19].
Strikingly, liver disease was the immediate or contributing
cause in 20.4% of the deaths that occurred in patients with
chronic hepatitis C. Liver disease was the only cause of death
Table 2. Cox Regression Analysis of Factors Associated With Mortality Among 2025 Patients
Crude Adjusted
a
Characteristics at Enrollment RR 95% CI P Value RR 95% CI P Value
HCV serostatus .008 .004
Cleared vs without HCV markers 1.1 .7–1.6 .68 0.9 .6–1.5 .82
Chronic vs without HCV markers 1.4 1.1–1.7 .002 1.5 1.2–1.9 .001
Self-reported hepatitis
HBV (yes vs no) 0.8 .6–1.0 .04
HAV (yes vs no) 1.1 .8–1.5 .46 1.5 1.1–2.1 .02
Demographics
Female vs male 1.2 1.0–1.4 .12
Black vs nonblack 1.3 1.1–1.5 .002
Age (per y) 1.00 .99–1.01 .97 1.01 1.00–1.02 .02
Birth cohort .35
<1945 vs ≥1965 1.2 .9–1.7 …
b
1945–1964 vs ≥1965 1.0 .8–1.2 …
b
Not college grad vs college grad 1.3 1.0–1.5 .02
HIV/AIDS history
IDU vs no IDU 1.3 1.0–1.6 .05
Time since AIDS diagnosis (per y) 1.01 .99–1.03 .48 1.02 1.00–1.05 .04
Diagnosis vs not diagnosis with CMV retinitis 1.8 1.5–2.2 <.0001 1.9 1.6–2.3 <.0001
On vs not on cART 0.5 .4–.6 <.0001
CD4
+ T-cell count <200 µL vs other AIDS-defining illness 1.0 .8–1.1 .65
Immunology and virology
CD4
+ T cells (per 100 cells/µL) 0.70 .66–.74 <.0001 0.82 .77–.88 <.0001
Nadir CD4
+ T cells (per 100 cells/µL) 0.71 .62–.82 <.0001
CD8
+ T cells (per 100 cells/µL) 0.93 .91–.94 <.0001
HIV RNA (per log copies/mL) 1.63 1.53–1.74 <.0001 1.47 1.37–1.58 <.0001
Max HIV RNA (per log copies/µL) 1.51 1.35–1.70 <.0001
Hematology
Platelet count (per 100 K cells/µL) 0.67 .60–.76 <.0001 0.87 .77–.99 .04
Year of enrollment .0007 .008
1998–2000 vs 2006–2009 1.7 1.2–2.3 .002 1.5 1.0–2.1 .03
2001–2005 vs 2006–2009 1.3 .9–1.8 .12 1.1 .8–1.6 .47
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; IDU, intravenous drug use; RR, relative risk.
a Variables selected from multiple Cox regression model regressing time to death on all variables listed above (except max HIV RNA because of 6% with missing
data) using forward selection entry criterion P <.05. There were 1833 complete cases.
b Not shown since overall P value is not significant.
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patients without HCV. The negative impact of liver disease on
survival emphasizes the need for patients with AIDS to be
aware of their HCV status so that they can fully participate in
their healthcare and risk reduction. Although current HCV
treatments lead to a sustained virological response (SVR) in
only 25%–50% of HIV/HCV coinfected patients [20–22], SVR
rates are expected to rise soon as direct-acting antiviral drugs
for HCV enter the clinic. SVR increases survival in HIV/HCV
coinfected patients [23] and reduces the risk of subsequent
antiretroviral-related toxicities [24]. Heightened HCV aware-
ness may increase the proportion of patients seeking treatment
and achieving an SVR; however, optimizing treatment and
managing drug-drug interactions will be signiﬁcant challenges
in the years ahead.
HCV-mediated liver disease was only one of the mortality
risks in the patients with chronic HCV infection. AIDS-
related conditions were immediate or contributing factors in
58.4% of the deaths. This percentage is similar to that of
patients without HCV. We did not ﬁnd any evidence that
HCV increased the immunological deﬁcits caused by HIV.
The relationship between HCV infection and immune
dysfunction is unresolved in the literature. HCV infection is
reported to blunt the CD4
+ T-cell response to cART, leading
to smaller increases in CD4
+ T-cell counts [1, 25–27];
however, maximal viral suppression is reported to mitigate
this effect [28]. We did not observe a blunted CD4
+ T-cell
response; however, HCV might have adverse effects on
immune function that are not reﬂected in CD4
+ T-cell counts.
HCV impairs dendritic cell function and alters CD8
+ T-cell
phenotype [29, 30]. It is possible that subtle immunological
effects of HCV reduced the resilience of patients with chronic
infection and rendered them more susceptible to a variety of
comorbid conditions, contributing to their increased overall
mortality.
In addition to HCV-mediated liver damage and immune
dysfunction, high-risk behaviors, including injection drug use
and heavy alcohol consumption, add signiﬁcantly to excess
morbidity and mortality in many groups of HIV/HCV-
coinfected individuals [5, 31, 32]. However, none of the
3 models of mortality risk in our study group showed an
association between injection drug use and mortality. Death
due to trauma, which is often a marker of high-risk behavior,
was not increased in patients with chronic hepatitis C. These
Table 3. Logistic Regression Analysis of Factors Associated With Failure to Accurately Self-report Positive Hepatitis C Virus (HCV)
Status Among 337 Patients With Chronic HCV Infection
Crude Adjusted
a
Characteristics at Enrollment OR 95% CI P Value OR 95% CI P Value
Demographics
Female vs male 0.8 .5–1.4 .39
Black vs nonblack 1.1 .7–1.7 .82
Age (per y) 0.97 .94–1.00 .05
Birth cohort .39
<1945 vs ≥1965 0.7 .2–3.0 …
b
1945–1964 vs ≥1965 1.4 .7–2.9 …
b
Not college grad vs college grad 0.6 .3–1.2 .15
Self-reported hepatitis
HBV (yes vs no) 0.6 .3–1.1 .09
HAV (yes vs no) 0.2 .1–.8 .02 0.3 .1–.9 .03
HIV/AIDS history
IDU vs no IDU 0.6 .4–1.0 .08
Time since AIDS diagnosis (per yr) 0.99 .93–1.04 .63
On vs not on cART 0.9 .5–1.5 .61
Year of enrollment .0001 .0002
1998–2000 vs 2006–2009 3.7 1.8–7.6 .0004 3.2 1.6–6.8 .002
2001–2005 vs 2006–2009 1.5 .7–3.1 .28 1.3 .6–2.7 .48
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatic C virus; HIV, human
immunodeficiency virus; IDU, intravenous drug use; OR, odds ratio.
a Multiple logistic regression model regressing probability of self-reported negative HCV on all variables listed above using forward selection entry criterion
P< .05. There were 329 complete cases.
b Not shown because overall P value is not significant.
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contribute signiﬁcantly to the excess mortality we observed in
patients with chronic HCV. Although high-risk behaviors
account for most HCV transmissions, it is signiﬁcant that past
HCV infection was not associated with increased mortality
risk in our study group. It thus appears that the high-risk
activities associated with HCV acquisition did not reduce
longevity in our cohort.
Considering the impact of end-stage liver disease on mor-
tality and the potential beneﬁts of HCV treatment, it is note-
worthy that almost one-third of the chronically infected
patients said that they had never been given a diagnosis of
HCV. Confusion with HAV or HBV did not account for this
underreporting. Research is needed to determine whether the
failure to accurately report positive HCV status reﬂected failure
of physicians to test for HCV, lack of communication, miscom-
munication, or denial. We found that lack of HCV awareness
was more likely in patients enrolled during the earliest part of
the study. Lack of HCV awareness was not associated with
race, injection drug use, or age, in contrast to a previous inves-
tigation of HIV-positive women and women at risk for HIV
infection. In those women, lack of HCV awareness was associ-
ated with black race and younger age [33]. Such disparate
results show that the factors contributing to lack of awareness
of HCV infection may differ between populations, underscor-
ing the need for broad-based HCV screening. It is estimated
that only about half of all the HCV-positive individuals in the
United States are aware of the infection [34].
The Department of Health and Human Services guidelines
for the prevention of opportunistic infections among HIV-
infected persons issued in 2002 advised screening for HCV in
all HIV-infected persons [35]. Identifying the most cost-effec-
tive screening approach is an important public health objective
but is challenging for several reasons: HIV-seropositive
patients with chronic HCV have a signiﬁcant rate of false-
negative anti-HCV antibody test results [36]; the more deﬁni-
tive HCV RNA test is more expensive than the antibody test;
and ongoing high-risk behaviors may lead to reinfection, re-
sulting in a need for periodic retesting. In this study, HCV
RNA tests were performed on about 25% of the study popu-
lation, with RNA testing directed to high-risk subjects (eg,
IDUs) and to subjects with positive antibody tests. Using this
targeted approach, an estimated 93% of HCV RNA–positive
cases were detected. Our failure to detect all of the cases indi-
cates that HCV RNA testing should be performed on HIV-
positive individuals who test HCV antibody negative but have
multiple HCV risk factors.
The strengths of this study include the large number of AIDS
patients (2025), the large number of HIV/HCV coinfected non-
IDUs (179), the prospective collection of data and plasma, the
long duration of follow-up (median, 6.1 years), the use of HCV
RNA testing to distinguish chronic from previous HCV infec-
tion, and the use of a testing algorithm that identiﬁed an esti-
mated 93% of the cases of chronic infection. The limitations
include the use of baseline data to analyze factors associated
with mortality and the lack of data about alcohol use.
Our results underscore the urgency of efforts to screen
AIDS patients for HCV and to make sure that the test results
and their implications are clearly communicated. A new era of
HCV treatment with direct acting antiviral drugs has just
begun. More effective treatments for both HIV and HCV will
undoubtedly decrease mortality in HCV-positive patients with
a diagnosis of AIDS. Early cure of HCV may avoid the costs
of liver transplantation, which exceed $123 000 per patient
[37]. Broader screening and more patient education are
needed to maximize the beneﬁts of new treatments and to
reduce liver-related mortality.
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